HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Broad-spectrum chemokine inhibition ameliorates experimental obliterative bronchiolitis.

AbstractBACKGROUND:
Obliterative bronchiolitis (OB) affects over half of all long-term survivors after lung transplantation. Respiratory epithelial cell injury, peribronchial inflammation, and proliferation of fibrovascular connective tissue causing airway occlusion characterize this lesion. Several chemokines participate in experimental OB, and singular blockade is only partially effective. We hypothesized that a broad-spectrum chemokine inhibitor would be an effective intervention in preventing the progression of OB in an established heterotopic tracheal transplantation model.
METHODS:
Tracheas from Brown-Norway or Lewis rats were transplanted subcutaneously into Lewis recipients. Treated, allogeneic recipients received either a broad-spectrum chemokine inhibitor in its active (NR58.3.14.3) or inactive (NR58.3.14.4) form at a dose of 30 mg/kg daily. Luminal obstruction, epithelial loss, leukocytic infiltrates, and inflammatory cytokine mRNA levels were assessed in explanted tracheal samples 14 days after transplantation.
RESULTS:
After 14 days, allografts receiving the inactive chemokine inhibitor demonstrated marked peribronchial inflammation, near complete loss of respiratory epithelium, and extensive intraluminal proliferation of fibrovascular connective tissue, with a mean 84% +/- 5% reduction in airway lumen cross-sectional area. Isografts showed limited inflammation, with minimal loss of epithelium and luminal occlusion. Allogeneic recipients treated with the active chemokine inhibitor showed a significant preservation of respiratory epithelium, minimal peribronchial inflammation, and a marked decrease in the loss of airway cross-sectional area (23% +/- 1%) (p < 0.001).
CONCLUSIONS:
These findings further characterize the participation of chemokines in OB, and suggest that broad-spectrum chemokine inhibition may potentially be a useful therapeutic tool in slowing the progression of this disease.
AuthorsBabu V Naidu, Alexander S Farivar, Baiya Krishnadasan, Steven M Woolley, David J Grainger, Edward D Verrier, Michael S Mulligan
JournalThe Annals of thoracic surgery (Ann Thorac Surg) Vol. 75 Issue 4 Pg. 1118-22 (Apr 2003) ISSN: 0003-4975 [Print] Netherlands
PMID12683548 (Publication Type: Journal Article)
Chemical References
  • Chemokines
  • Peptides, Cyclic
  • cyclo(cysteinyl-glutaminyl-isoleucyl-tryptophyl-lysyl-glutaminyl-lysyl-prolyl-aspartyl-leucyl-cysteinyl-amide)
Topics
  • Animals
  • Bronchiolitis Obliterans (drug therapy, prevention & control)
  • Chemokines (antagonists & inhibitors, physiology)
  • Disease Progression
  • Male
  • Peptides, Cyclic (administration & dosage, therapeutic use)
  • Postoperative Complications (drug therapy, prevention & control)
  • Rats
  • Rats, Inbred BN
  • Rats, Inbred Lew
  • Trachea (pathology, transplantation)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: